PHA Canada is committed to ensuring that all PH patients have access to the best possible care and treatment at diagnosis and beyond. We work to empower and support patients, caregivers, family, and friends—along with members of the PH medical community—to advocate to federal, provincial, and territorial governments on issues that are important to our community. Your support helps our voice be heard.
Since June 2015, PHA Canada has been working with the pulmonary arterial hypertension (PAH) and scleroderma communities to advocate for publicly funded access to all Health Canada-approved treatments for PAH. We continue to be concerned about disparities that exist in the quality of care PAH patients may receive depending on what province or territory they live in or whether they have private insurance.
The Canadian PAH community is hopeful that provincial and territorial governments will continue to support PAH patients and fund all remaining Health Canada-approved treatments, such as Opsumit® (macitentan, which is currently only available through public funding in Québec), and Adempas® (riociguat, which is not publicly funded anywhere in Canada).
PHA Canada is pleased to report that the pan-Canadian Pharmaceutical Alliance (pCPA) successfully concluded pricing negotiations for Opsumit on December 23, 2020. The last step in the reimbursement process is for each province to sign a Product Listing Agreement (PLA) with the manufacturer of Opsumit to make the treatment accessible to patients who can benefit from it.
If you are a patient or a caregiver who would like to share your opinions on Opsumit with elected officials in your province, please click here to contact us today.
Check out Take Action PAH for campaign updates and more information on how to get involved.